1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Ward, B.P.
Ma, D.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C4 H9 N O2
103.120
n
ALPHA-AMINOISOBUTYRIC ACID
L-peptide linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H9 N O4
147.129
GAMMA-L-GLUTAMIC ACID
L-GLUTAMIC ACID
L-gamma-peptide, C-delta linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
H2 N
16.023
AMINO GROUP
non-polymer
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C16 H32 O2
256.424
PALMITIC ACID
non-polymer
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
Structural Changes Associated with Peptide Lipidation Broaden Biological Function
10.2210/pdb2m5p/pdb
pdb_00002m5p
3446.849
Glucagon
1
syn
polymer
147.129
GAMMA-L-GLUTAMIC ACID
2
syn
non-polymer
256.424
PALMITIC ACID
1
syn
non-polymer
no
yes
H(AIB)QGTFTSDYSKKLD(AIB)RRAQDFVQWLMNT(NH2)
HAQGTFTSDYSKKLDARRAQDFVQWLMNTX
X
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_database_status
struct_conn
struct_ref_seq_dif
repository
Initial release
Database references
Derived calculations
Other
1
0
2013-03-27
1
1
2023-06-14
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
_struct_conn.pdbx_dist_value
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.ptnr1_auth_comp_id
_struct_conn.ptnr1_auth_seq_id
_struct_conn.ptnr1_label_asym_id
_struct_conn.ptnr1_label_atom_id
_struct_conn.ptnr1_label_comp_id
_struct_conn.ptnr1_label_seq_id
_struct_conn.ptnr2_auth_comp_id
_struct_conn.ptnr2_auth_seq_id
_struct_conn.ptnr2_label_asym_id
_struct_conn.ptnr2_label_atom_id
_struct_conn.ptnr2_label_comp_id
_struct_conn.ptnr2_label_seq_id
_struct_ref_seq_dif.details
HELIX
DETERMINATION METHOD: AUTHOR DETERMINED
BMRB
Y
RCSB
2013-03-03
REL
REL
REL
REL
GGL
GAMMA-L-GLUTAMIC ACID
PLM
PALMITIC ACID
9606
human
Homo sapiens
sample
structures with the lowest energy
100
10
2D 1H-1H TOCSY
2D 1H-1H NOESY
0.7
mM
20
mM
0.02
4.7
ambient
298
K
simulated annealing
1
closest to the average
0.7 mM peptide, 20 mM sodium phosphate, 90% H2O/10% D2O
90% H2O/10% D2O
BRUNGER
refinement
XPLOR-NIH
800
Varian
Varian Uniform NMR System
LYX
13
2
GGL
GGL
101
X
LYX
13
2
GGL
GGL
102
X
LYX
13
3
PLM
PLM
103
X
HIS
1
n
1
HIS
1
X
AIB
2
n
2
AIB
2
X
GLN
3
n
3
GLN
3
X
GLY
4
n
4
GLY
4
X
THR
5
n
5
THR
5
X
PHE
6
n
6
PHE
6
X
THR
7
n
7
THR
7
X
SER
8
n
8
SER
8
X
ASP
9
n
9
ASP
9
X
TYR
10
n
10
TYR
10
X
SER
11
n
11
SER
11
X
LYS
12
n
12
LYS
12
X
LYX
13
n
13
LYS
13
X
LEU
14
n
14
LEU
14
X
ASP
15
n
15
ASP
15
X
AIB
16
n
16
AIB
16
X
ARG
17
n
17
ARG
17
X
ARG
18
n
18
ARG
18
X
ALA
19
n
19
ALA
19
X
GLN
20
n
20
GLN
20
X
ASP
21
n
21
ASP
21
X
PHE
22
n
22
PHE
22
X
VAL
23
n
23
VAL
23
X
GLN
24
n
24
GLN
24
X
TRP
25
n
25
TRP
25
X
LEU
26
n
26
LEU
26
X
MET
27
n
27
MET
27
X
ASN
28
n
28
ASN
28
X
THR
29
n
29
THR
29
X
THR
29
n
30
NH2
30
X
author_defined_assembly
1
monomeric
X
AIB
2
ALPHA-AMINOISOBUTYRIC ACID
A
AIB
2
ALA
X
AIB
16
ALPHA-AMINOISOBUTYRIC ACID
A
AIB
16
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
X
X
HZ1
HE
LYS
ARG
13
17
1.27
2
X
X
O
H
AIB
GLY
2
4
1.32
4
X
X
HZ1
HH21
LYS
ARG
13
17
1.27
6
X
X
H
H
GLN
ASP
20
21
1.30
8
X
X
HE2
HE22
HIS
GLN
1
3
1.19
8
X
X
HZ2
H
LYS
GGL
12
102
1.23
8
X
X
HH21
HH11
ARG
ARG
17
18
1.26
1
X
AIB
2
-151.50
56.83
1
X
GLN
3
-19.77
-40.96
1
X
THR
5
-47.44
-17.14
1
X
PHE
6
-109.63
-65.28
1
X
SER
8
-61.95
1.34
1
X
LYS
13
170.86
-95.25
1
X
AIB
16
-66.35
5.80
1
X
ALA
19
74.68
-57.57
1
X
GLN
20
162.91
-23.82
1
X
LEU
26
-101.23
56.58
1
X
MET
27
-156.74
-52.60
2
X
AIB
2
173.92
-17.75
2
X
GLN
3
52.34
-51.88
2
X
THR
5
-47.38
-17.95
2
X
THR
7
-62.71
5.93
2
X
SER
8
-65.47
-91.38
2
X
ASP
9
-25.87
-59.17
2
X
LYS
12
-150.54
69.62
2
X
LYS
13
63.97
-112.66
2
X
ARG
18
-66.85
4.64
2
X
ALA
19
80.12
-55.10
2
X
GLN
20
158.41
-24.94
2
X
ASP
21
-52.68
-9.73
2
X
TRP
25
-39.39
-73.31
2
X
LEU
26
-82.35
33.26
2
X
MET
27
-139.33
-72.70
3
X
AIB
2
-150.84
56.68
3
X
GLN
3
-20.54
-40.44
3
X
SER
8
-42.77
-81.00
3
X
ASP
9
-25.65
-52.16
3
X
LYS
12
-166.40
-76.55
3
X
LYS
13
-168.13
-86.36
3
X
AIB
16
-62.95
5.74
3
X
ALA
19
76.53
-52.36
3
X
GLN
20
138.84
63.83
3
X
ASP
21
-154.22
-50.09
3
X
PHE
22
23.67
-123.06
3
X
MET
27
-122.52
-59.29
4
X
AIB
2
-151.18
56.74
4
X
GLN
3
-20.33
-40.67
4
X
SER
8
-50.79
-7.17
4
X
SER
11
-133.80
-34.26
4
X
LYS
13
160.49
-90.14
4
X
ALA
19
73.04
-52.56
4
X
GLN
20
157.70
-25.79
4
X
LEU
26
-94.24
43.13
4
X
MET
27
-137.07
-47.77
5
X
AIB
2
-150.82
57.27
5
X
GLN
3
-19.06
-41.17
5
X
THR
5
-47.82
-15.83
5
X
THR
7
-62.06
5.64
5
X
SER
8
-69.22
-104.66
5
X
ASP
9
-10.72
-52.56
5
X
LYS
12
-91.26
-91.09
5
X
LYS
13
-153.10
-81.27
5
X
AIB
16
-77.55
40.29
5
X
ALA
19
74.30
-49.33
5
X
GLN
20
132.11
54.83
5
X
ASP
21
-136.77
-40.22
5
X
PHE
22
33.57
-88.11
5
X
VAL
23
-107.11
43.43
5
X
GLN
24
38.65
29.49
6
X
AIB
2
-151.61
56.97
6
X
GLN
3
-20.25
-40.50
6
X
THR
5
-46.98
-15.20
6
X
PHE
6
-107.96
-62.33
6
X
SER
8
-64.65
1.34
6
X
ASP
9
-105.89
-63.10
6
X
LYS
13
31.44
-99.04
6
X
AIB
16
-62.89
8.43
6
X
ARG
18
-146.15
-109.69
6
X
ALA
19
46.90
12.24
6
X
GLN
20
-165.53
0.58
6
X
TRP
25
-37.95
-74.70
6
X
LEU
26
-77.32
31.94
7
X
AIB
2
-151.42
56.38
7
X
GLN
3
-20.36
-40.30
7
X
THR
5
-44.32
-18.47
7
X
SER
8
-56.59
-6.32
7
X
ASP
9
-92.18
-64.15
7
X
LYS
12
-109.97
-74.65
7
X
LYS
13
-149.23
-78.15
7
X
ASP
15
-75.11
-76.61
7
X
AIB
16
0.34
-64.95
7
X
ARG
17
-34.81
-39.54
7
X
ARG
18
-129.23
-122.44
7
X
ALA
19
44.22
17.68
7
X
GLN
20
-172.54
34.32
7
X
ASP
21
-170.34
-40.77
7
X
PHE
22
34.01
-89.14
7
X
VAL
23
-103.83
42.07
7
X
GLN
24
41.85
24.80
7
X
ASN
28
-47.48
-15.64
8
X
AIB
2
-148.51
58.21
8
X
GLN
3
-15.35
-43.75
8
X
LYS
12
-145.98
-89.04
8
X
LYS
13
-162.99
-85.16
8
X
ARG
18
-132.94
-132.35
8
X
ALA
19
56.33
10.00
8
X
GLN
20
-165.10
18.00
8
X
ASP
21
-158.21
-44.09
8
X
PHE
22
33.99
-88.30
8
X
VAL
23
-98.34
42.34
8
X
LEU
26
41.82
26.36
8
X
MET
27
80.83
94.74
8
X
ASN
28
39.78
33.79
9
X
AIB
2
-150.77
56.26
9
X
GLN
3
-17.33
-41.51
9
X
THR
5
-45.49
-17.19
9
X
PHE
6
-119.23
-70.37
9
X
THR
7
-62.76
7.43
9
X
SER
8
-72.45
-90.95
9
X
ASP
9
-20.02
-43.93
9
X
LYS
12
-128.94
-81.25
9
X
LYS
13
-174.05
-84.25
9
X
ARG
18
-126.70
-125.13
9
X
ALA
19
48.84
14.56
9
X
GLN
20
-170.41
20.24
9
X
ASP
21
-162.87
-58.49
9
X
PHE
22
35.76
-88.67
9
X
VAL
23
-95.94
44.60
9
X
LEU
26
41.42
25.16
9
X
MET
27
81.19
94.30
9
X
ASN
28
39.44
27.10
10
X
AIB
2
-150.67
57.07
10
X
GLN
3
-19.67
-40.92
10
X
THR
5
-44.72
-17.56
10
X
ASP
9
-95.87
-63.35
10
X
LYS
12
-113.95
-80.87
10
X
LYS
13
-147.90
-102.43
10
X
ASP
15
-112.91
53.02
10
X
AIB
16
-164.41
-12.46
10
X
ARG
18
-77.80
30.04
10
X
ALA
19
73.61
-55.07
10
X
GLN
20
161.38
-25.69
10
X
ASP
21
-49.03
-15.47
10
X
ASN
28
77.87
-18.49
Solution structure of lipidated glucagon analog in water
1
N
N
2
N
N
2
N
N
3
N
N
X
THR
7
A
THR
7
HELX_P
X
LYS
12
A
LYS
12
5
1
6
X
ASP
21
A
ASP
21
HELX_P
X
TRP
25
A
TRP
25
1
2
5
covale
1.320
both
X
HIS
1
A
C
HIS
1
1_555
X
AIB
2
A
N
AIB
2
1_555
covale
1.320
both
X
AIB
2
A
C
AIB
2
1_555
X
GLN
3
A
N
GLN
3
1_555
covale
1.325
one
X
LYS
13
A
NZ
LYS
13
1_555
X
GGL
101
B
CD
GGL
1_555
covale
1.329
both
X
ASP
15
A
C
ASP
15
1_555
X
AIB
16
A
N
AIB
16
1_555
covale
1.331
both
X
AIB
16
A
C
AIB
16
1_555
X
ARG
17
A
N
ARG
17
1_555
covale
1.220
both
X
THR
29
A
C
THR
29
1_555
X
NH2
30
A
N
NH2
30
1_555
covale
1.318
both
X
GGL
101
B
N
GGL
1_555
X
GGL
102
C
CD
GGL
1_555
covale
1.336
both
X
GGL
102
C
N
GGL
1_555
X
PLM
103
D
C1
PLM
1_555
LIPID BINDING PROTEIN
GLUCAGON, DIABETES, OBESITY, LIPIDATED, LIPID BINDING PROTEIN
GLUC_HUMAN
UNP
1
53
P01275
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
53
81
2M5P
1
29
P01275
X
1
1
29
1
SER
engineered mutation
AIB
2
2M5P
X
P01275
UNP
54
2
1
TYR
engineered mutation
LYS
13
2M5P
X
P01275
UNP
65
13
1
SER
engineered mutation
AIB
16
2M5P
X
P01275
UNP
68
16
1
amidation
NH2
30
2M5P
X
P01275
UNP
30
BINDING SITE FOR LINKED RESIDUES X 101 to 103
Software
8
X
GLN
3
A
GLN
3
8
1_555
X
THR
5
A
THR
5
8
1_555
X
SER
8
A
SER
8
8
1_555
X
LYS
12
A
LYS
12
8
1_555
X
LYS
13
A
LYS
13
8
1_555
X
ARG
17
A
ARG
17
8
1_555
X
ARG
18
A
ARG
18
8
1_555
X
LEU
26
A
LEU
26
8
1_555
1
P 1